The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519595-87-00

Acronym

192024-092

Enrollment

Registered

2024-12-18

Start date

2015-12-15

Completion date

Unknown

Last updated

2025-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular hypertension, Open-angle glaucoma

Brief summary

Study eye time-matched IOP change from baseline (follow-up minus time-matched baseline) at each hour evaluated (Hours 0 and 2).

Detailed description

Time-matched IOP

Interventions

DRUGTimolol vehicle

DRUGBimatoprost SR sham applicator

DRUGTimolol

DRUGBimatoprost SR

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Study eye time-matched IOP change from baseline (follow-up minus time-matched baseline) at each hour evaluated (Hours 0 and 2).	—

Secondary

Measure	Time frame
Time-matched IOP	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026